SecBot SecBot
Biotech Drug Report Generated Aug 18, 2026

INVEGA SUSTENNA

JNJ·JOHNSON & JOHNSON
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Approved, marketed in the U.S. since July 31, 2009
Why 3/10
No hard, dated binary catalyst exists for this molecule in the next ~12 months: INVEGA SUSTENNA was FDA-approved on 2009-07-31, it is already fully commercialized, and there is no pending PDUFA, pivotal readout, or label-expansion decision for it, so per the rubric the score is capped in the 3-5 band and set at 3 because it is one mature product inside a diversified mega-cap (JNJ) where it can drive no concentrated move.
Actionable Insight NEUTRAL

For a JNJ investor, INVEGA SUSTENNA is a mature, likely-eroding cash-flow product inside a diversified healthcare giant, not a catalyst to trade. Watch quarterly J&J earnings (pharma segment Invega franchise sales) and any FDA action on generic or biosimilar long-acting injectable paliperidone for erosion signals; a decisive bull/bear case on JNJ should be built on its oncology/immunology pipeline (e.g., RYBREVANT) and medtech, not this 2009-vintage antipsychotic.

Price Chart

Loading chart...

Executive Summary

INVEGA SUSTENNA is Johnson & Johnson's long-acting injectable atypical antipsychotic (paliperidone palmitate), FDA-approved since July 31, 2009 and one of a family of Invega products. As an approved, mature product inside a $262 mega-cap with a 22-analyst buy-rated consensus, the drug carries no pending regulatory binary and is best read as a slow-erosion cash-flow asset (generic oral paliperidone already exists, ANI Pharmaceuticals' ANDA204452, and FDA label updates continued through 2026) rather than a share-price catalyst.

How It Works

Paliperidone is an atypical antipsychotic (per FDA's own drug classification) used mainly to treat schizophrenia. INVEGA SUSTENNA is the long-acting injectable version: instead of a daily pill, the drug is injected and releases slowly from the injection site over weeks, which helps patients who struggle to take daily medication. Antipsychotics work by dampening overactive dopamine/serotonin signaling in the brain that drives hallucinations and delusions.

Trial Status

Fully approved and commercialized: SecBot's catalyst records show INVEGA SUSTENNA (paliperidone palmitate) received FDA approval on 2009-07-31, joining the Invega family of J&J products (oral INVEGA approvals 2006-12-19 and 2007-04-27, and INVEGA HAFYERA approval 2015-05-18). No company-sponsored Phase 2/3 paliperidone trials appear in SecBot's pipeline data, only academic studies. The regulatory story today is class-level: FDA safety-labeling actions across paliperidone products in 2026 (boxed warning on increased mortality in elderly dementia-related psychosis) apply to the oral generic products of ANI Pharmaceuticals and Bryant Ranch Prepack.

The Two-Sided Case

▲ Bull Case4
Established, long-approved franchise: FDA approval catalyst recorded 2009-07-31, with the broader Invega family (INVEGA oral 2006/2007, INVEGA HAFYERA 2015) showing J&J extended the franchise across dosing intervals.
Parent-company strength: JNJ closed at $262.37 (2026-08-17) with a 52-week high of $274.90, analyst consensus of 22 covering analysts at mean price target $272.50 with recommendationMean 1.91 (buy) and zero downgrades in the last 120 days.
Broad institutional ownership and accumulation: BlackRock ($53.9B), State Street ($34.0B) and JPMorgan ($15.1B) hold JNJ per 2026-Q2 13F data, and the 90-day evidence checklist shows multiple tracked funds adding/doubling JNJ positions in Q2 2026.
Paliperidone remains a standard antipsychotic with ongoing, managed FDA labeling, recent 2026 label actions are routine boxed-warning updates, not safety withdrawals.
▼ Bear Case4
No binary left: the drug-specific catalyst (approval) happened 17 years ago, the historical reaction around the 2009 approval was a -1.46% 1-day / -2.17% 5-day move, illustrating how little a single mature product moves a mega-cap.
Generic erosion pressure: generic oral paliperidone products (ANI Pharmaceuticals ANDA204452; Bryant Ranch ANDA218755 repackaging) carry active FDA safety-labeling actions in 2026, evidence the paliperidone market has commoditized, though these are the oral form, not the injectable.
Company-level sentiment is mixed: CEO Joaquin Duato sold ~102,315 shares at $261 and ~20,976 at $262 on 2026-08-13 (gross ~$26.7M + ~$5.5M per Form 4), and JNJ's FINRA daily short-volume ratio hit ~0.62 on 2026-08-17, elevated-flow flags, not a squeeze setup given short interest of only ~1.05% of estimated shares outstanding (2026-07-31).
No hard, dated catalyst: no PDUFA, pivotal readout, or label-expansion decision is scheduled for INVEGA SUSTENNA, so there is no event around which to size a position.

Upcoming Catalysts

  • None scheduled for INVEGA SUSTENNA specifically (no PDUFA/readout in the next ~12 months).
  • Company-level: quarterly J&J earnings where Invega franchise sales are reported (latest 8-K/10-Q filings).
  • Watch for FDA label/approval actions on any generic or biosimilar paliperidone palmitate long-acting injectable.
  • Class-wide paliperidone safety-labeling updates, which continued through mid-2026.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

JOHNSON & JOHNSON 8-K JNJ ·Originating report

Sources · 6

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov6 sec.gov